Methods of administering a mixture of fatty acids for the treatment of non-human mammals
Mixture of fatty acids, their derivatives, ester or methyl ester derivates thereof, which may be administered to non-human mammals by diffusion in to ambient air during at least seven consecutive days, with a rapid kinetic of diffusion during the first three days of administration.
1. A method of delivering a composition comprising a mixture of pure fatty acids, methyl or ethyl ester derivatives thereof, in a sufficient amount to a non-human mammal by controlled diffusion in the ambient air over a period of at least seven consecutive days with a kinetic of diffusion of 2-3 mg/h during the first three days, about 1.5 to 2 mg/h on the fourth day, about 1 mg/h on the fifth and the sixth days and less than 0.5 mg/h on the seventh day so as to treat symptoms linked to stress or anxiety in said non-human mammal, wherein the said composition does not contain solvent, excipients, vegetable extracts, or even aqueous phase, wherein the controlled diffusion is carried out at a temperature between 100° C. and 140° C., with the proviso that the composition is not an aerosol spray and the controlled diffusion is achieved without addition of any polymer.
2. The method according to claim 1 , wherein said composition is pure, non-emulsified or is not dissolved and further does not contain any vegetable extract, vegetable extract of valeriana, and/or aqueous phase.
3. The method according to claim 1 , wherein a total of 240 mg of said fatty acids, ester or methyl ester derivatives thereof, are administered to said non-human mammal by diffusion during the seven consecutive days of treatment.
4. The method according to claim 1 , wherein said composition comprises a therapeutically effective amount of at least one fatty acid chosen among azelaic acid, pimelic acid, capric acid, lauric acid, myristic acid, palmitic acid, palmitoleic acid, oleic acid, linoleic acid, stearic acid, archidonic acid, n-butyric acid, isobutyric acid, a-methylbutyric acid, caproic acid, pivalic acid, γ-linoleic acid, eicosapentanoic acid, pentadecanoic acid, docosahexenoic acid, or ester or methyl ester derivatives thereof.
5. The method according to claim 4 , wherein said composition further comprises a therapeutically effective amount of oleic acid, or ester or methyl ester derivatives thereof.
6. The method according to the claim 5 , wherein said composition further comprises a therapeutically effective amount of palmitic acid, or ester or methyl ester derivatives thereof.
7. A method of reducing stress and anxiety of a non-human mammal, of preventing urinary markings, of familiarizing the non-human mammal with a new environment, of preventing stamping or destruction of territory, of noisy outbursts, of dirtiness, of aggressiveness, and/or of reducing recurring idiopathic cystitis, the method comprising administering a therapeutically effective amount of a composition comprising a mixture of pure fatty acids or methyl or ethyl ester derivatives thereof, to the non-human mammal by controlled diffusion with a kinetic of diffusion of 2-3 mg/h during the first three days, about 1.5 to 2 mg/h on the fourth day, about 1 mg/h on the fifth and the sixth days and less than 0.5 mg/h on the seventh day.
8. A kit for reducing the stress and anxiety in a non-human mammal, the kit comprising a composition comprising a mixture of pure fatty acids or methyl or ethyl ester derivatives thereof, wherein the kit administers the mixture to the non-human mammal by controlled diffusion in the ambient air with a kinetic of diffusion of 2-3 mg/h during the first three days, about 1.5 to 2 mg/h on the fourth day, about 1 mg/h on the fifth and the sixth days and less than 0.5 mg/h on the seventh day, the kit further comprising technical instructions.
9. A method of delivering to a non-human mammal a composition comprising a mixture of pure fatty acids, or their methyl or ethyl ester derivatives thereof, wherein the mixture is delivered in a sufficient amount to the non-human mammal by controlled diffusion in the ambient air over a period of at least seven consecutive days with a kinetic of diffusion of,
(i) higher than about 1.5 mg/h during the first five days, then
(ii) about 0.5 to 1 mg/h on the sixth day, and then finally
(iii) less than 0.5 mg/h on the seventh day;
wherein the method is used for treating symptoms linked to stress or anxiety in said non-human mammal, wherein the said composition does not contain solvent, excipients, vegetable extracts, or even aqueous phase, wherein the diffusion is carried out at a temperature between 100° C. and 140° C., with the proviso that the composition is not an aerosol spray and the controlled diffusion is achieved without addition of any polymer.